1. Chidamide, a novel histone deacetylase inhibitor, inhibits laryngeal cancer progression in vitro and in vivo.
- Author
-
Liu, Xinyu, Li, Wenjing, Xu, Licheng, Chen, Xiaoxue, Zhao, Rui, Guo, Yan, Ge, Jingchun, Yang, Zhenming, Li, Liang, Zhang, Jiarui, Cao, Jing, Shao, Yue, Guo, Xinyue, Tian, Linli, and Liu, Ming
- Subjects
- *
HISTONE deacetylase inhibitors , *LARYNGEAL cancer , *CANCER invasiveness , *HISTONE deacetylase , *ANIMAL experimentation , *PYROPTOSIS , *ANTINEOPLASTIC agents - Abstract
Although surgery is an important treatment for laryngeal cancer, surgery has a significant negative impact on the quality of life of patients, and many patients have poor tolerance to surgery. Therefore, alternative chemotherapeutic drugs are an important research hotspot. Chidamide is a histone deacetylase inhibitor that selectively inhibits the expression of type I and IIb histone deacetylases (1, 2, 3 and 10). It has a significant anticancer effect on a variety of solid tumours. This study verified the inhibitory effect of chidamide on laryngeal carcinoma. We conducted a variety of cellular and animal experiments to explore how chidamide inhibits the development of laryngeal cancer. The results showed that chidamide had significant antitumour activity against laryngeal carcinoma cells and xenografts and could induce cell apoptosis, ferroptosis and pyroptosis. This study provides a potential option for the treatment of laryngeal cancer. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF